Acute optic neuritis
Unmet clinical needs and model for new therapies
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 12, 2015
- Accepted in final form May 13, 2015
- First Published July 23, 2015.
Author Disclosures
- Steven L. Galetta, MD,
- Pablo Villoslada, MD,
- Netta Levin, MD, PhD,
- Kenneth Shindler, MD, PhD,
- Hiroshi Ishikawa, MD,
- Edward Parr, PhD,
- Diego Cadavid, MD and
- Laura J. Balcer, MD, MSCE
- Steven L. Galetta, MD,
NONE
NONE
Biogen and Genzyme
(1) Neurology, Editorial Board; (2) Journal of Neuro-ophthalmology, Editorial Board
NONE
NONE
NONE
Genzyme Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pablo Villoslada, MD,
Roche, Novartis, Neurotec Farma, Bionure Farma; Consultant: Novartis, Roche, TFS, Heidelberg Engineering, MedImmune, Digna Biotec, Neurotec Pharma
NONE
Novartis
PloSONE Academic editor since 2011, Neurology & Therapy, Curr There Op Neurol
1. Methyltioadenosine for the treatment of MS 2. Agonistic neurotrophic compounds for the treatment of brain diseases 3. Gene signature pattern as a biomarker for MS
NONE
NONE
NONE
NONE
NONE
NONE
unrestricted grants from, Novartis Roche
Instituto de Salud Carlos III, European Commission,
NONE
Fundacion Maraton TV3
Bionure Pharma
NONE
NONE
NONE
NONE
NONE
- Netta Levin, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kenneth Shindler, MD, PhD,
NONE
NONE
1) Medical College of Wisconsin, Speaker Honorarium 2) Temple University, Speaker Honorarium
1) Frontiers in Neuro-Ophthalmology, Associate Editor, 2011 - present
NONE
1) Tolosa Hunt Syndrome, UpToDate, Authorship Honorarium 2004 - 2015 2) Neuro-Ophthalmology, Oakstone Publishing, Authorship Honararium 2014
NONE
Consultation in the form of medical record review and independent medical examinations of medical-legal cases for various law firms and insurance companies. Several cases each year.
NONE
NONE
NONE
1) Stemnion, Inc.
1) NIH, EY019014, PI 2010-present
NONE
1) RPB 2) ITMAT 3) F.M. Kirby Foundation
NONE
NONE
NONE
NONE
NONE
Consultation in the form of medical record review and independent medical examinations of medical-legal cases for various law firms and insurance companies. Several cases each year.
- Hiroshi Ishikawa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01-EY013178, P30 EY008098, Co-investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Edward Parr, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Excel Scientific Solutions*, medical writer, 10 years (*contracted by Biogen Idec to provide writing support for this manuscript)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Diego Cadavid, MD and
NONE
NONE
I'm a full time paid employee of Biogen, a biopharmaceutical company involved in research and development in the field related to the published article.
NONE
I'm listed as an inventor on pending patent applications related to the use of drugs that block LINGO-1 to treat demyelination in multiple sclerosis.
NONE
I'm a full time paid employee of Biogen and own stock and restricted stock units in Biogen.
NONE
NONE
NONE
NONE
I have been a full time paid employee of Biogen for over 7 years.
NONE
NONE
NONE
I own restricted stock units and stock as compensation for my full time employment at Biogen.
NONE
NONE
I own restricted stock units and stock as compensation for my full time employment at Biogen.
NONE
NONE
- Laura J. Balcer, MD, MSCE
Biogen, Genzyme
NONE
(1) Biogen, consulting; (2) Genzyme, consulting;
NONE
NONE
NONE
NONE
Biogen Idec, Novartis, Vaccinex, Questcor, Acorda
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (S.L.G., L.J.B.), Ophthalmology (S.L.G., L.J.B.), and Population Health (L.J.B.), New York University School of Medicine, New York, NY; Center of Neuroimmunology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic of Barcelona (P.V.), Barcelona, Spain; Department of Neurology (P.V.), University of California, San Francisco; Department of Neurology (N.L.), The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew-University Medical Center, Jerusalem, Israel; Scheie Eye Institute and FM Kirby Center for Molecular Ophthalmology (K.S.), University of Pennsylvania, Philadelphia; UPMC Eye Center (H.I.), Eye and Ear Institute, Ophthalmology and Visual Science Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, PA; Department of Bioengineering (H.I.), Swanson School of Engineering, University of Pittsburgh, PA; Excel Scientific Solutions (E.P.), Southport, CT; and Biogen (D.C.), Cambridge, MA.
- Correspondence to Dr. Balcer: laura.balcer{at}nyumc.org
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Drugs and Devices
The application of optical coherence tomography in neurologic diseasesRamiro S. Maldonado, Pradeep Mettu, Mays El-Dairi et al.Neurology: Clinical Practice, September 17, 2015 -
Articles
Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritisR. T. Naismith, N. T. Tutlam, J. Xu et al.Neurology, June 29, 2009 -
Article
Optical coherence tomography is highly sensitive in detecting prior optic neuritisSarah Chaoying Xu, Randy H. Kardon, Jacqueline A. Leavitt et al.Neurology, January 23, 2019 -
Article
No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MSMarco Pisa, Simone Guerrieri, Giovanni Di Maggio et al.Neurology, November 15, 2017